Modular Effector Mechanisms, Superior Precision and Routine Production Processes All Lend to a Lowering of Healthcare Costs
In addition to delivering superior therapies, Elstar’s UniTI™ platform promises to address a major economic issue facing the healthcare community: the high cost of combining two or more drugs to maximize therapeutic efficacy. In the field of immuno-oncology, the cost of treating cancer patients with multiple drugs and/or cell-based therapies generates excessive and untenable treatment costs. Elstar is naturally positioned to build molecules that combine multiple functionalities to engage biological pathways that are currently being targeted separately.
Elstar’s multi-functional antibodies are designed to be no more costly than a single antibody therapeutic, while delivering high impact therapeutic benefit.